<DOC>
	<DOCNO>NCT01276769</DOCNO>
	<brief_summary>This study compare effective Paclitaxel combine Epirubicin Paclitaxel plus Carboplatin neoadjuvant treatment TNBC . And investigator hypothesize paclitaxel combine carboplatin sensitive TNBC compare Paclitaxel plus Epirubicin , study also look relation BRCA1 mutation sensitive carboplatin .</brief_summary>
	<brief_title>Comparison Study Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment Triple-negative Breast Cancer</brief_title>
	<detailed_description>It know triple-negative breast cancer ( TNBC ) aggressive non-triple negative breast cancer pathological feature clinical prognosis , standard chemotherapy regimens especially TNBC . NCCN guideline recommend Paclitaxel Epirubicin base regimen preferred regimen adjuvant chemotherapy treatment Recurrence Metastatic breast cancer.The combination two drug consider strong arrangement therefore , common use Triple negative breast cancer patient poor prognosis . According result retrospective study , platinum-based chemotherapy regimen show promising sensitive Triple negative breast cancer patient compare regimen without platinum . This study compare effective Paclitaxel combine Epirubicin Paclitaxel plus Carboplatin neoadjuvant treatment TNBC . And investigator hypothesize paclitaxel combine carboplatin sensitive TNBC compare Paclitaxel plus Epirubicin , study also look relation BRCA1 mutation sensitive carboplatin .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Women age 18 70 year ; WHO Performance status ( ECOG ) 0 1 Core biopsy histologically proven ⅡaⅢc phase breast cancer ( regardless type ) ; Immunohistochemisty（IHC）：ER，PR，CerB2；Triple negative （ERPRHer2） Hormone receptor negativity define ER &lt; 10 % , PR &lt; 10 % ( IHC ) , HER2 negativity define IHC 01+ , [ IHC 2+ FISH CISH negative ] ； Adequate hematological function ( neutrophil count ³ 2x109/l , platelet count ³ 100x 109/l , Hemoglobin &gt; 9 g/dl ) ; Adequate hepatic function : ASAT ALAT £ 1.5 ULN alkaline phosphatases £ 2.5 ULN , total bilirubin £ 1,5 ULN ; Adequate renal function : serum creatinine £ 1.5 ULN ; Adequate cardiac function , LEVF value &gt; 50 % Muga scan echocardiography，and electrocardiogram doe show specific abnormality； Patients accept contraception intake overall length treatment childbearing potential ; Signed write informed consent . Any tumor ³ T4a ( UICC1987 ) ( cutaneous invasion , deep adherence , inflammatory breast cancer ) ; ER+ PR+ Her2 overexpression Any chemotherapy , hormonal therapy radiotherapy Previous cancer precede 10 year ; Patients already include another therapeutic trial involve experimental drug ; Patients concurrent severe and/or uncontrolled medical disease infection could compromise participation study ; LEVF &lt; 50 % ( MUGA scan echocardiography ) ; Clinically significant cardiovascular disease ( e.g . unstable angina , congestive heart failure , uncontrolled hypertension ( &gt; 150/90 ) , myocardial infarction cerebral vascular accident ) within 6 month prior chemotherapy ; Known prior severe hypersensitivity reaction agent receive ; Women pregnant breastfeeding . Adequate birth control measure take study treatment phase ; Women positive pregnancy test en enrollment prior study drug administration ; Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial ; Individual deprive liberty place authority tutor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Triple Negative Breast Cancer</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Platinum</keyword>
</DOC>